An even greater understanding of the benefits and limitations of old and new antifungal agents is reflected in this edition of Therapeutic Guidelines in Systemic Fungal Infections. Each table has been revised to present antifungal treatment as it is used today, taking into account evidence-based recommendations that have been made since the publication of the first and second editions. New diagnostic tests such as PCR and ELISA have been assessed in immunocompromised patients. These may assist in the choice of antifungal and may be used to monitor treatment success or failure. The number of oral and parenteral antifungal agents has increased significantly and new formulations of established agents have been licensed in many countries. Furthermore, antifungal susceptibility testing has been refined. Significant progress has been made in determining the applications of these tests in routine clinical practice. The use of these tests is indicated where appropriate. As previously, we have included the most relevant key publications and reviews at the ends of the tables. These provide a link to a far larger body of established literature.Therapeutic Guidelines in Systemic Fungal Infection. 3rd Ed.exe
